Table 1.
Clinical and demographic characteristics of the study population.
| N = 156 | n (%) |
|---|---|
| Sex | |
| Men | 87 (55.8) |
| Women | 69 (44.2) |
| Median age, years (IQR) | 42 (28–55) |
| Disease type | |
| UC | 76 (48.7) |
| CD | 80 (51.3) |
| Median BMI, kg/m2 (IQR) | 23.9 (21.6–27.8) |
| Current smoker | |
| Smoker | 27 (17.3) |
| Former smoker | 61 (39.1) |
| Non-smoker | 68 (43.6) |
| Marital status | |
| Married/partner | 94 (60.3) |
| Divorced/Single/ Widowed | 62 (39.7) |
| Education | |
| Low level (secondary school or lower) | 107 (68.6) |
| High level (college or higher) | 49 (31.4) |
| Have children | 92 (59) |
| Active employee | 83 (53.2) |
| Comorbidity | 66 (42.3) |
| Previous history of MAD | 14 (9) |
| CD Montreal classification (n: 80) | |
| Age group | |
| A2: 17–40 years | 44 (55) |
| A3: ≥40 years | 36 (45) |
| Location of Crohn’s (>1 location possible) | |
| L1: Ileal | 42 (52.5) |
| L2: Colonic | 12 (15) |
| L3: Ileocolonic | 25 (31.3) |
| L4: Upper GI | 6 (7.5) |
| Crohn’s behavior | |
| B1: Inflammatory | 63 (78.8) |
| B2: Stricturing | 11 (13.8) |
| B3: Penetrating | 6 (7.5) |
| Perianal involvement | 5 (6.3) |
| UC Montreal classification (n: 76) | |
| E1: Proctitis | 22 (28.9) |
| E2: Left-sided colitis | 30 (39.5) |
| E3: Extensive colitis | 24 (31.6) |
| Active IBD at diagnosis | |
| Mild | 93 (59.6) |
| Moderate/Severe | 63 (40.4) |
| Median CRP, mg/L (IQR) | 0.7 (0.2–4.5) |
| Median fecal calprotectin, μg/g (IQR) | 619 (92–1,718) |
| Anemia | 47 (30.1) |
| Use of mesalazine | 110 (70.5) |
| Use of steroids | 104 (66.7) |
| Use of thiopurinics | 34 (21.8) |
| Use of biologics | 37 (23.7) |
| IBD-related surgery | 6 (3.8) |
| Hospitalization | 71 (45.5) |
| EIMs | 19 (12.2) |
Values are n (%) unless otherwise noted. IQR, Interquartile range; UC, Ulcerative colitis; CD, Crohn’s disease; BMI, Body mass index; MAD, Mood and/or anxiety disorders; GI, gastrointestinal; IBD, Inflammatory bowel disease; CRP, C-reactive protein; and EIMs, Extra-intestinal manifestations.